Yahoo
NYSE American - Delayed Quote USD

Xtant Medical Holdings, Inc. (XTNT)

0.2894 -0.0106 (-3.53%)
At close: November 6 at 4:00:00 PM EST
Chart Range Bar
Loading chart for XTNT
  • Previous Close 0.3000
  • Open 0.2931
  • Bid 0.2757 x 30000
  • Ask 0.3400 x 50000
  • Day's Range 0.2757 - 0.3072
  • 52 Week Range 0.2700 - 0.8400
  • Volume 62,871
  • Avg. Volume 1,704,509
  • Market Cap (intraday) 40.599M
  • Beta (5Y Monthly) -0.25
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0800
  • Earnings Date (est.) Nov 10, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 1.03
  • Moby Rating Neutral

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.

xtantmedical.com

151

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

XTNT
62.90%
S&P 500 (^GSPC)
7.76%

1-Year Return

XTNT
63.37%
S&P 500 (^GSPC)
9.77%

3-Year Return

XTNT
75.47%
S&P 500 (^GSPC)
68.96%

5-Year Return

XTNT
74.61%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 23.03M
Earnings -9.41M
Profit Margin -40.87%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
10M
20M
30M
-40.0%
-30.0%
-20.0%
-10.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

0.60
1.03 Average
0.2894 Current
1.50 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/2/2026
Analyst LUCID CAPITAL MARKETS
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 1

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -10.17%

  • Return on Assets (ttm)

    -3.75%

  • Return on Equity (ttm)

    -25.16%

  • Revenue (ttm)

    109.53M

  • Net Income Avi to Common (ttm)

    -11.14M

  • Diluted EPS (ttm)

    -0.0800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.87M

  • Total Debt/Equity (mrq)

    65.01%

  • Levered Free Cash Flow (ttm)

    10.13M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: